Abstract: A fuel control system for an engine includes a closing module and a purge control module. The closing module commands closing of a purge valve in response an engine speed transitioning from greater than a predetermined speed to less than the predetermined speed while the purge valve is in an open state. The predetermined speed is less than a predetermined target speed of the engine and is greater than zero. The purge control module transitions the purge valve from the open state to a closed state in response to the command.

Abstract: A system according to the present disclosure includes a valve control module, a purge fraction module, and a diagnostic module. The valve control module opens a purge valve in an evaporative emissions system to allow purge vapor to flow to an intake system of an engine. The purge fraction module determines first and second fractions of purge vapor delivered to the engine relative to a total amount of air and purge vapor delivered to the engine based on first and second inputs, respectively. The first input is from a hydrocarbon sensor disposed in the evaporative emissions system of the engine. The second input is from an oxygen sensor disposed in an exhaust system of the engine. The diagnostic module selectively diagnoses a fault in at least one of the evaporative emissions system and the hydrocarbon sensor based on the first and second purge fractions when the purge valve is open.

Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.

Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.

Abstract: A system according to the principles of the present disclosure includes a storage capability module and at least one of an engine speed control module and a spark control module. The storage capability module determines a capability of a catalytic converter to store oxygen. The engine speed control module controls a speed of an engine based on the oxygen storage capability of the catalytic converter. The spark control module controls a spark timing of the engine based on the oxygen storage capability of the catalytic converter.

Abstract: A machine is provided for preparing a desired product from a capsule containing desired ingredients. The machine includes a brew chamber that is adapted to hold the capsule at a downward angle relative to a horizontal plane. A cover for the brew chamber is adapted to move between an open position and a closed position. A loading mechanism is provided for extending and retracting the brew chamber. An injection system is provided for injecting a fluid into the capsule. A fluid transfer system is provided for transferring a desired fluid from a fluid source to the injection system. A dispensing system is provided for dispensing product to a receptacle. A reusable capsule is also provided for use with the machine.

Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.

Abstract: Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.

Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.

Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.

Abstract: A machine is provided for preparing a desired product from a capsule containing desired ingredients. The machine includes a brew chamber that is adapted to hold the capsule at a downward angle relative to a horizontal plane. A cover for the brew chamber is adapted to move between an open position and a closed position. A loading mechanism is provided for extending and retracting the brew chamber. An injection system is provided for injecting a fluid into the capsule. A fluid transfer system is provided for transferring a desired fluid from a fluid source to the injection system. A dispensing system is provided for dispensing product to a receptacle. A reusable capsule is also provided for use with the machine.

Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.

Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.

Abstract: Power distribution systems and methods are described. In one example, a method of testing a power distribution zone select interlocking system including a first circuit protection device and a second circuit protection device coupled to the first circuit protection device downstream of the first circuit protection device is described. The method includes receiving, by the second circuit protection device, an input instructing the second circuit protection device to test communication between the first circuit protection device and the second circuit protection device, and outputting, by the second circuit protection device, a blocking signal in response to the input. The first circuit protection display an indication of reception of the blocking signal to confirm proper interconnection of the zone select interlocking signals.

Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.

Abstract: A fuel control system for a vehicle includes a pressure compensation module that compensates an intake oxygen signal based on an intake pressure signal and that generates a compensated intake oxygen signal. A blow-by estimation module generates an estimated blow-by flow. A purge flow estimation module estimates the purge flow based on the compensated intake oxygen signal and the estimated blow-by flow. A fuel control estimation module reduces fueling to injectors of an engine of the vehicle based on the purge flow.